VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 121 filers reported holding VERVE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $268,551 | -64.6% | 55,031 | -3.7% | 0.00% | – |
| Q1 2024 | $759,112 | +109.3% | 57,162 | +119.7% | 0.00% | – |
| Q4 2023 | $362,691 | +35.7% | 26,018 | +29.1% | 0.00% | – |
| Q3 2023 | $267,295 | -29.6% | 20,158 | -0.5% | 0.00% | – |
| Q2 2023 | $379,857 | +19.3% | 20,259 | -8.3% | 0.00% | – |
| Q1 2023 | $318,408 | +1.2% | 22,081 | +35.8% | 0.00% | – |
| Q4 2022 | $314,593 | -94.5% | 16,258 | -90.2% | 0.00% | -100.0% |
| Q3 2022 | $5,674,000 | +2722.9% | 165,176 | +1159.1% | 0.00% | – |
| Q2 2022 | $201,000 | -11.1% | 13,119 | +32.5% | 0.00% | – |
| Q1 2022 | $226,000 | -16.0% | 9,899 | +35.7% | 0.00% | – |
| Q4 2021 | $269,000 | +8.5% | 7,293 | +38.4% | 0.00% | – |
| Q3 2021 | $248,000 | – | 5,269 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |